Abstracts tagged "pain"

Abstract Number: 1886 • ACR Convergence 2025
Thirty Percent of Older Adults with Rheumatic Disease Receive High-Risk Medication
Christine Anastasiou¹, Eric Roberts², gabriela Schmajuk³ and Jinoos Yazdany⁴, ¹Stanford University, Pleasanton, CA, ²University of California, San Francisco, SF, CA, ³University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA, ⁴UCSF, San Francisco, CA
Background/Purpose: High-risk medications (HRMs) may increase the risk of adverse events such as falls and fractures, hospitalizations, hospital length of stay, and death in older…
Abstract Number: 1424 • ACR Convergence 2025
Mapping Central Nervous System Responses To Painful Stimuli In Patients With Axial Spondyloarthritis
Mohamad Bittar¹, Yvonne Lee², Atul Deodhar³, Jennifer Barton⁴ and Alexander Stevens¹, ¹Oregon Health & Science University, Portland, OR, ²Northwestern University, Chicago, IL, ³Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ⁴VA Portland Health Care System/OHSU, Portland, OR
Background/Purpose: Chronic pain is one of the common causes of disability in axial spondyloarthritis (axSpA). The mechanism behind this pain is not well understood, hindering…
Abstract Number: 1236 • ACR Convergence 2025
Vestibulocortical Stimulation via Caloric Irrigation in Nociplastic Disease: Therapeutic Effects on Pain, Autonomic Functioning & Quality of Life Measures
Michael Kaplan¹, Alexandra Canori², Rebecca Howard², Talia Torkian³, Rebecca Pietro¹, Gabriela Santiago-Pichardo¹, Daniel Clauw⁴, David Putrino², Yousaf Ali¹, Laura Tabacof² and Trung Ngo⁵, ¹Division of Rheumatology, Mount Sinai Hospital, New York, ²Department of Rehabilitation and Human Performance, Icahn School of Medicine at Mount Sinai, New York, ³Division of Rheumatology, Icahn School of Medicine at Mount sinai, New York, ⁴Chronic Pain and Fatigue Research Center, University of Michigan, Ann Arbor, MI, ⁵RECOVER Injury Research Centre, The University of Queensland and Surgical, Treatment & Rehabilitation Service (STARS), Queensland, Australia
Background/Purpose: Fibromyalgia (FM) and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) are prototypical nociplastic disorders marked by centralized pain & fatigue, respectively. Nociplastic symptoms — such as…
Abstract Number: 1046 • ACR Convergence 2025
Cannabis Knowledge, Attitudes, and Practices Among Rheumatology Providers: Implications for Clinical Care and Education
Joanna Zeiger¹, Patti Katz², Mary-Ann Fitzcharles³, Stuart Kassan⁴, Teresa Simon⁵ and Kaleb Michaud⁶, ¹Canna Research Foundation, Boulder, CO, ²UCSF, San Rafael, CA, ³McGill University, Montreal-West, Canada, ⁴National Jewish Health, Denver, CO, ⁵Physicians Research Center, LLC, Toms River, NJ, ⁶University of Nebraska Medical Center, Omaha, NE
Background/Purpose: As medical cannabis becomes increasingly integrated into clinical care, healthcare providers—particularly those managing chronic rheumatologic conditions—must navigate wide-ranging levels of knowledge, attitudes, and prescribing…
Abstract Number: 0455 • ACR Convergence 2025
Assessment of Pain Outcomes in Pooled Phase 3 Trials of a Selective, Tyrosine Kinase 2 Inhibitor, Deucravacitinib, in Patients With Active Psoriatic Arthritis
Lihi Eder¹, Philip J. Mease², Vibeke Strand³, Alexis Ogdie⁴, Atul Deodhar⁵, Rebecca Haberman⁶, April Armstrong⁷, Alice B. Gottlieb⁸, David Roberts⁹, Laurie Eliason¹⁰, Stefan Varga¹¹, Eleni Vritzali¹², Janice Li¹¹ and Laure Gossec¹³, ¹University of Toronto, Toronto, ON, Canada, ²Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ³Stanford University School of Medicine, Palo Alto CA, Portola Valley, CA, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ⁶NYU Langone Health, New York, NY, ⁷University of California Los Angeles, Los Angeles, CA, USA, Los Angeles, CA, ⁸Department of Dermatology, UT Southwestern Medical Center, Dallas, TX, ⁹Bristol Myers Squibb, Uxbridge, United Kingdom, ¹⁰Bristol Myers Squibb,, Princeton, NJ, ¹¹Bristol Myers Squibb, Princeton, NJ, ¹²Bristol Myers Squibb, Boudry, Switzerland, ¹³Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France
Background/Purpose: Patients rate pain as one of the most important aspects of psoriatic arthritis (PsA). Pain signaling involves a series of cytokines, including those downstream…
Abstract Number: 2261 • ACR Convergence 2025
Palindromic Rheumatism and Predictors of Progression to Rheumatoid Arthritis: Experience from a Tertiary Care Center in Northern India
Sryla Punjadath¹, Venkatesh Srinivasa Pai¹, Prativa Priyadarshani Sethi¹, ritu sangwan², Abhishek Rai³ and Ravi Kant¹, ¹All India Institute of Medical Sciences, Rishikesh, Rishikesh, Uttarakhand, India, ²AIIMS ,Rishikesh, Rishikesh, Uttarakhand, India, ³AIIMS ,RISHIKESH, Bhilai, Chhattisgarh, India
Background/Purpose: Palindromic Rheumatism (PR) is recognized as a clinical syndrome of intermittent episodes of pain, swelling, and erythema in and around joints, which are severe…
Abstract Number: 1804 • ACR Convergence 2025
Pharmacology of LEVI-04, a novel treatment for OA
Simon Westbrook¹ and Kerry af Forselles², ¹Levicept Ltd, Sandwich, United Kingdom, ²Levicept, Sandwich, United Kingdom
Background/Purpose: LEVI-04 is a novel fusion protein comprising the extracellular domain of p75 neurotrophin receptor (p75NTR) coupled to IgG1 Fc, being developed for the treatment…
Abstract Number: 1380 • ACR Convergence 2025
Phenotyping Neuropathic Pain in Sjögren’s Disease: A Cluster-Based Approach
Beatrice Dei¹, Stefano Donati¹, Gaetano La Rocca², Giovanni Fulvio¹, Federico Fattorini¹, Antonello Sulis¹, Michele Moretti¹, Elena Elefante¹, Francesco Ferro³, Giulia Ricci⁴, Marta Mosca⁵ and Chiara Baldini⁵, ¹Rheumatology Unit, University of Pisa, Pisa, Toscana, Italy, ²University of Pisa, Rheumatology Unit, Pisa, Pisa, Italy, ³Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Pisa, Italy, ⁴Neurology Unit, University of Pisa, Pisa, Toscana, Italy, ⁵University of Pisa, Pisa, Pisa, Italy
Background/Purpose: Neuropathic pain (NeP) is increasingly recognized as a relevant symptom domain in primary Sjögren’s disease (SjD), contributing to the disease burden beyond glandular involvement.…
Abstract Number: 1234 • ACR Convergence 2025
Serum Antibodies Against Glial Fibrillary Acidic Protein in Fibromyalgia: A Proof-of-Concept Study
Felipe Massó¹, Laura Aline Martinez-Martinez², Luis M Amezcua-Guerra³, Francisco Mercado⁴, Angélica Almanza⁵ and Manuel Martínez-Lavín¹, ¹Instituto Nacional de Cardiologia Ignacio Chavez, Mexico city, Mexico, ²Rheumatology Department at National Institute of Cardiology Ignacio Chávez, Mexico City, Federal District, Mexico, ³Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, Mexico city, ⁴Instituto Nacional de Psiquiatría Ramón del la Fuente Muñiz, Mexico city, Mexico, ⁵Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Mexico city, Mexico
Background/Purpose: Fibromyalgia (FM) is a stress-related disorder in which dorsal root ganglia (DRG) may play a pivotal pathogenetic role. DRG exhibit unique stress-induced, pro-algesic physio-anatomy,…
Abstract Number: 1027 • ACR Convergence 2025
GLP-1 Receptor Agonists to Facilitate Weight Loss and Improve Disease Activity, Pain and Function in Patients With Rheumatic and Musculoskeletal Disease: Real-World Evidence From the Rheumatology Informatics System for Effectiveness (RISE) Registry
Nick McCormick¹, Jingyi Zhang², Emily Holladay², Fenglong Xie³ and Jeffrey Curtis⁴, ¹Auburn University, Auburn, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³The University of Alabama at Birmingham, Birmingham, AL, ⁴Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL
Background/Purpose: Glucagon-like peptide-1 receptor agonists (GLP-1 RA) such as semaglutide (SEM; GLP-1) and tirzepatide (TIR; GIP/GLP-1), were initially approved for type 2 diabetes management but…
Abstract Number: 0442 • ACR Convergence 2025
Beyond the Joints: The Impact of Non-Articular Pain on Patient-Reported Function in a Longitudinal Real-World Early RA Cohort
Charis Meng¹, Marie-France Valois², Caci Julia³, Yvonne Lee⁴, Bindee Kuriya⁵, Gilles Boire⁶, Hugues Allard-Chamard⁷, Carol Hitchon⁸, Louis Bessette⁹, Glen Hazlewood¹⁰, Carter Thorne¹¹, Susan J. Bartlett¹², Janet Pope¹³ and Vivian Bykerk¹, ¹Hospital for Special Surgery, New York, NY, ²McGill University, Pointe-Claire, QC, Canada, ³Hospital for Special Surgery, New York, ⁴Northwestern University, Chicago, IL, ⁵Mount Sinai Health, Toronto, Canada, ⁶Retired, Sherbrooke, QC, Canada, ⁷Université de Sherbrooke, Sherbrooke, Canada, ⁸University of Manitoba, Winnepeg, Canada, ⁹Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec, QC, Canada, ¹⁰University of Calgary, Calgary, AB, Canada, ¹¹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²McGill University, Beaconsfield, QC, Canada, ¹³University of Western Ontario, London, ON, Canada
Background/Purpose: A third of patients with early (e)RA report pain outside the joint or non-articular pain (NAP) despite RA treatment(1). NAP, both regional and widespread,…
Abstract Number: 2120 • ACR Convergence 2025
Analyzing Gender and Racial Disparities in Paget’s Disease of Bone: A Large-Scale Observational Study
Kinga Grzybowski¹, Ahmer Khan² and Arthur Lau³, ¹Jefferson Einstein Montgomery Hospital, Maspeth, NY, ²Jefferson Einstein Philadelphia Hospital, Philadelphia, ³Jefferson Einstein Hospital, Maple Glen, PA
Background/Purpose: Osteitis deformans, commonly referred to as Paget’s Disease of the Bone (PDB), affects adults over the age of 55, mainly of European descent and…
Abstract Number: 1800 • ACR Convergence 2025
The Role of Nociceptor-Expressed Piezo2 in Nervous System Immune Cell Infiltration in a Mouse Model of Osteoarthritis
Natalie Adamczyk¹, Terese Geraghty², Shingo Ishihara³, alia obeidat², Jun Li², Anne-Marie Malfait² and Rachel Miller¹, ¹Rush University Medical Center, Chicago, IL, ²Rush University Medical Center, Chicago, ³Rush University, Chicago
Background/Purpose: Osteoarthritis is one of the leading causes of chronic pain and disability worldwide with 500 million people affected. We have previously reported that nociceptor-conditional…
Abstract Number: 1298 • ACR Convergence 2025
Identifying Psychosocial Profiles in Youth with Chronic Musculoskeletal Pain: A K-Means Clustering Analysis of Resilience Subgroups
Sabrina Gmuca¹, Jan Leonard², Alexis Z. Tomlinson², Mackenzie McGill², Nellie Butler², Rui Xiao³, Peter F. Cronholm³, Tonya M. Palermo⁴, Jami F. Young⁵, Abby R. Rosenberg⁶ and Pamela Weiss⁷, ¹Children's Hospital of Philadelphia; University of Pennsylvania, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia, ³University of Pennsylvania, Philadelphia, PA, ⁴University of Washington School of Medicine; Seattle Children’s Research Institute, Seattle, ⁵Children's Hospital of Philadelphia; University of Pennsylvania, Philadelphia, ⁶Dana-Farber Cancer Institute; Boston Children’s Hospital; Harvard Medical School, Boston, ⁷Childrens Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Psychological resilience is low among youth with chronic musculoskeletal pain (CMP) at baseline. We aimed to explore resilience profiles among youth with CMP during…
Abstract Number: 1235 • ACR Convergence 2025
Demystifying Pain in patients with Lupus: How much is it Lupus and How much is it Other Stuff?
Meenakshi Jolly, Rush University, Chicago
Background/Purpose: Pain in patients with Systemic Lupus Erythematosus (SLE) is not well understood. There is role of active disease in pain (e.g. arthritis, serositis) also…

« Previous Page
1
…
4
5
6
7
8
…
44
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].